拉米夫定联合硫普罗宁对乙型肝炎肝纤维化的临床效果观察

Clinical Observation of Lamivudine Combined with Tiopronin in the Treatment of Hepatic Fibrosis in Patients with Chronic Hepatitis B

目的:观察拉米夫定联合硫普罗宁对乙型肝炎肝纤维化肝功能和血清学指标的影响。方法:慢性乙型肝炎肝纤维化患者150例随机分为3组,分别应用拉米夫定、硫普罗宁、拉米夫定联合硫普罗宁治疗,并用生化分析仪检测血清丙氨酸转氨酶(ALT)、天门冬氨酸转氨酶(AST)、γ谷酰氨转肽酶(GGT),放免法测定血清纤维化指标透明质酸(HA)、层粘蛋白(LN)、Ⅳ型胶原(C-Ⅳ)和Ⅲ型前胶原肽(PCⅢ)的情况。结果:治疗后3组肝功能和血清学肝纤维化指标均有明显改善(P<0.05),C组比A、B组改善明显(P<0 05)。结论:拉米夫定和硫普罗宁单独应用可以改善慢性乙型肝炎肝纤维化患者的病情,二者联合应用效果更强。

Objective：Observe lamivudine joint Tiopronin for hepatitis b liver fibrosis,liver function and serological indexes. Methods： 150 cases chronic hepatitis b iiver fibrosis patients were randomly divided into 3 groups respectively,application of lamivudine,ti opronin,lamivudine with tiopronin detection,and biochemical analyzer alanine aminotransferase（serum ALT）,aspartic acid aminotransferase （AST）,γ-glutamyl transferase （GGT）,radioimmunoassay deterination of serum fibrosis indices of hyaluronic acid （HA）,layer mucin （LN）,Ⅳ type （C-Ⅳ） and collagen type Ⅲ PCⅢ peptide.Results：After treatment,the three groups of liver and serological index of liver fibrosis were improved significantly （P〈0.05）,group C than A,B group improved significanil~ （P〈0.05）.ConcluSion：Lamivudine and Tiopronin alone can be used to improve the chronic hepatitis b liver fibrosis of the patient, combined application effect.